The meta-analysis results showed that ESR1 PvuII (C>T) polymorphism is not linked to the risk of prostate cancer under all genetic models (T allele vs. C allele: OR  =  1.10, 95%CI: 0.91–1.33, P = 0.332; TT + TC vs. CC: OR = 1.05, 95%CI: 0.91–1.21, P = 0.478; TT vs. CC + CT: OR = 1.21, 95%CI: 0.87–1.69, P = 0.255; TT vs. CC: OR = 1.26, 95%CI: 0.85–1.86, P = 0.256; TT vs. CT: OR = 1.19, 95%CI: 0.87–1.61, P = 0.277; respectively). Here, ESR1 is linked to prostate cancer.